NIP
KALV

Nicholas Investment Partners’s KalVista Pharmaceuticals KALV Stock Holding History

Nicholas Investment Partners’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-184,358
Closed -$2.17M – 235
2024
Q2 		$2.17M Buy
184,358
+1,714
+0.9% +$20K 0.23% 139
2024
Q1 		$2.17M Buy
+182,644
New +$2.44M 0.22% 147
2021
Q4 		– Sell
-217,389
Closed -$3.79M – 204
2021
Q3 		$3.79M Sell
217,389
-433,514
-67% -$8.79M 0.28% 121
2021
Q2 		$15.6M Buy
650,903
+56,773
+10% +$1.49M 0.98% 36
2021
Q1 		$15.3M Buy
+594,130
New +$15.6M 1.06% 33

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Nicholas Investment Partners's KALV Position: Q3 2024 in Review

Nicholas Investment Partners sold out of KalVista Pharmaceuticals (KALV) in Q3 2024, closing a stake of 184,358 shares — an estimated $2.17M sold.

Nicholas Investment Partners first reported a position in KALV in Q1 2021 and held it in 5 quarters. The position peaked at $15.6M in Q2 2021. 122 funds tracked by Wall St. Rank hold KALV as of Q3 2024.

  • Nicholas Investment Partners reported no remaining KalVista Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Nicholas Investment Partners sold 184,358 KalVista Pharmaceuticals shares in Q3 2024, an estimated $2.17M.
  • Nicholas Investment Partners first reported a position in KalVista Pharmaceuticals in Q1 2021 and held it in 5 quarters.
  • Nicholas Investment Partners's KalVista Pharmaceuticals position peaked at $15.6M in Q2 2021.
  • 122 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q3 2024.

Based on Nicholas Investment Partners's 13F filing for Q3 2024, filed 12 Nov 2024.